The expanded product range offers tailor-made solutions for customers with specific bioprocessing requirements Watson-Marlow Fluid Technology Group (WMFTG) announces the expansion of its puresu® single-use range, providing a combination of components that are safe and easy-to-install. PureSu is ideal for the end-to-end manufacture of biopharmaceuticals and personalised medicines, such as gene therapies. The expanded range consists of three new product options: sterile claim, gamma irradiated and non-irradiated. WMFTG’s puresu assemblies offer a unique solution to the challenges of bioprocessing, providing controlled, efficient and reliable Single-Use assemblies that simplifies validation processes. Offering open architecture design by using the single-use components customer can quickly create a sterile, fluid path that meets their specific bioprocessing needs. With the addition of sterile puresu WMFTG now offers three product variants which each offer distinct benefits. Sterile puresu is an optimal solution for critical fluid path bioprocesses and customers who require contamination risk mitigation. Gamma irradiated puresu is suitable for customers who manage microbial control ...